Loading cancer entity…
Loading cancer entity…
Clinical trials
4,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (703)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01393509 | The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies | completed | Phase 1 | 47 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT02561988 | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | completed | Phase 1 | 86 | Blueprint Medicines CorporationINDUSTRY | 2 | Mar 17, 2023 | clinicaltrials |
| NCT05448599 | A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS | unknown | Phase 1 / Phase 2 | 120 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT03878927 | CPX-351+GO in Subjects 55 Years Old, or Older, With AML(CPX GO) | terminated | Phase 1 | 11 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | withdrawn | Phase 1 | 0 | Shanghai Pudong HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03303339 | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05740917 | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS | unknown | Phase 1 | 82 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT02056782 | A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia(PGX-AML) | completed | Phase 1 | 12 | Jazz PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 18 | Telios Pharma, Inc.INDUSTRY | 8 | Feb 17, 2023 | clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03194932 | Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | completed | Phase 1 | 62 | St. Jude Children's Research HospitalOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT03895112 | MPN-RC 118 AVID200 in Myelofibrosis | completed | Phase 1 | 21 | John MascarenhasOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT02543749 | DC Vaccination in CML | terminated | Phase 1 / Phase 2 | 1 | Charite University, Berlin, GermanyOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) | terminated | Phase 1 | 22 | Magenta Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 43 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 96 | Fate TherapeuticsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05367700 | A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. | recruiting | Phase 1 | 108 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 13, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT05665075 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 19 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05665114 | Natural Killer(NK) Cell Therapy in r/r AML | unknown | Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02996474 | Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 10 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 28, 2022 | clinicaltrials |
| NCT00887926 | Study of IMC-EB10 in Participant With Leukemia | terminated | Phase 1 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT03393611 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | terminated | Phase 1 | 8 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04866056 | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | terminated | Phase 1 / Phase 2 | 1 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 16 | Prelude TherapeuticsINDUSTRY | 1 | Nov 15, 2022 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT04038437 | A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML | completed | Phase 1 | 35 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04022785 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 0 | Oct 31, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT01586455 | Human Placental-Derived Stem Cell Transplantation(HPDSC) | completed | Phase 1 | 43 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01373515 | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 12 | MendusINDUSTRY | 1 | Oct 10, 2022 | clinicaltrials |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | terminated | Phase 1 | 2 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT03516760 | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 36 | AvenCell Europe GmbHINDUSTRY | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | terminated | Phase 1 | 70 | AstraZenecaINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT01555268 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT02287233 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 94 | AbbVieINDUSTRY | 4 | Aug 29, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Mar 28, 2023source: clinicaltrials